Gamida Cell Ltd. (GMDA)
Company Description
Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious hematologic diseases.
The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with high-risk hematologic malignancies, as well as in Phase I/II clinical trials in patients with severe aplastic anemia.
It is also developing GDA-201, a natural killer cell-based cancer immunotherapy, which is in Phase I/II studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma.
In addition, the company is developing NK cell pipeline comprising GDA-301, GDA-401, GDA-501, and GDA-601 to treat hematologic malignancies and solid tumors.
The company was founded in 1998 and is headquartered in Jerusalem, Israel.
| Country | IL |
| IPO Date | Oct 26, 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 143 |
| CEO | Abigail L. Jenkins |
Contact Details
Address: 5 Nahum Heftsadie Street Jerusalem, IL | |
| Website | https://www.gamida-cell.com |
Stock Details
| Ticker Symbol | GMDA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001600847 |
| CUSIP Number | M47364100 |
| ISIN Number | IL0011552663 |
| Employer ID | 00-0000000 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Abigail L. Jenkins | President, Chief Executive Officer & Director |
| Mary Theresa Coelho M.B.A. | Chief Financial Officer, Principal Financial Officer & Principal Accounting Officer |
| Dr. Ronit Simantov M.D. | Chief Medical Officer & Chief Scientific Officer |
| Dr. Tracey Lodie Ph.D. | Scientific Advisor & Consultant |
| Joshua F. Patterson | General Counsel & Chief Compliance Officer |
| Linda Stamler | Vice President of Marketing & Account Management |
| Michele Ilene Korfin M.B.A., R.Ph. | Chief Operating & Chief Commercial Officer |
| Naftali Brikashvili CPA | Senior Vice President Finance & Operations |
| Penny Bushell | Chief Human Resource Officer |
| Vladimir Melnikov | Senior Vice President of Global Operations & Manufacturing |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 24, 2024 | 15-12G | Filing |
| May 24, 2024 | 8-K | Current Report |
| May 23, 2024 | 10-Q | Quarterly Report |
| May 16, 2024 | NT 10-Q | Filing |
| May 10, 2024 | 8-K/A | [Amend] Current Report |
| May 09, 2024 | S-8 POS | Filing |
| May 09, 2024 | S-8 POS | Filing |
| May 09, 2024 | S-8 POS | Filing |
| May 09, 2024 | POS AM | Filing |
| May 09, 2024 | POS AM | Filing |